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Abstract
OBJECTIVE—To assess the immunogenicity of thermostable live-attenuated rabies virus 
(RABV) preserved by vaporization (PBV) and delivered to the duodenal mucosa of a wildlife 
species targeted by an oral vaccination program.
ANIMALS—8 gray foxes (Urocyon cinereoargenteus).
PROCEDURES—Endoscopy was used to place RABV PBV, alginate-encapsulated RABV PBV, 
or nonpreserved RABV into the duodenum of each fox. Blood samples were collected weekly to 
monitor the immune response. Saliva samples were collected weekly and tested for virus shedding 
by use of a conventional reverse-transcriptase PCR assay. Foxes were euthanized 28 days after 
vaccine administration, and relevant tissues were collected and tested for presence of RABV.
RESULTS—2 of 3 foxes that received RABV PBV and 1 of 2 foxes that received nonpreserved 
RABV seroconverted by day 28. None of the 3 foxes receiving alginate-encapsulated RABV PBV 
seroconverted. No RABV RNA was detected in saliva at any of the time points, and RABV 
antigen or RNA was not detected in any of the tissues obtained on day 28. None of the foxes 
displayed any clinical signs of rabies.
CONCLUSIONS AND CLINICAL RELEVANCE—Results for this study indicated that a live-
attenuated RABV vaccine delivered to the duodenal mucosa can induce an immune response in 
gray foxes. A safe, potent, thermostable RABV vaccine that could be delivered orally to wildlife 
or domestic animals would enhance current rabies control and prevention efforts.
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Most of the rabies cases in humans occur in developing countries where canine rabies is 
enzootic and access to rabies biologics is limited.1,2 The cost associated with canine rabies is 
estimated at $124 billion annually3, and it is estimated that there are 26,000 to 86,000 cases 
of rabies in humans annually as a result of exposure to canine rabies.4,5 It is believed that 
almost all of these cases could be prevented by elimination of canine rabies and proper 
administration of postexposure prophylaxis.6,7 Poor veterinary health infrastructure in 
countries with enzootic canine rabies has led to proposals to vaccinate children against 
rabies prior to exposure.8
In countries in which canine rabies has been eliminated, wildlife serve as a dominant 
reservoir. Oral vaccination against rabies is a proven strategy to prevent rabies in wildlife 
and thus spillover to domestic animals or humans.9–11 Rabies vaccines for oral 
administration must be stored cold (5° ± 3°C) before distribution to the environment.12–16 
Stability of current vaccines differs, with some vaccines stable up to 12 months at 45°C15 
and others stable up to 3 months at 37°C17; however, no manufacture recommends vaccine 
be stored at ambient temperature because of the risk for loss of potency.
The foam drying technique PBV effectively stabilizes RABV at ambient temperatures (30° 
± 7°C) for at least 15 months.18 The RABV PBV vaccine can induce RABV-neutralizing 
antibodies when delivered IM and protects mice from challenge exposure.18 One advantage 
of PBV is the ability to micronize biologics, which allows for needle-free and traditional 
pharmaceutical delivery (eg, intradermal microneedle patches, intranasal inhaler, dissolvable 
oral gels, or gastric capsules).19,20 Investigators who attempted intestinal delivery of rabies 
vaccine found a limited response for multiple doses of an inactivated vaccine administered 
by this route to red foxes (Vulpes vulpes)21 and raccoons (Procyon lotor).22
In the study reported here, endoscopy was used to place live-attenuated nonencapsulated 
RABV PBV vaccine, alginate-encapsulated RABV PBV vaccine, or non-PBV RABV 
vaccine into the duodenum of gray foxes (Urocyon cinereoargenteus). Endoscopy was used 
to ensure delivery of vaccines to the intestinal mucosa. The study was required as a proof-of-
concept for development of future vaccines designed for intestinal delivery. Alginate 
encapsulation was used for vaccine formulation on the basis of results of a study23 that 
indicated increased protection and persistence of the antigen. Gray foxes were selected for 
use because these mesocarnivores are the most abundant and widely distributed species of 




Gray foxes were purchased from a vendor.a Blood samples were collected by veterinary staff 
at the vendor and used to determine that all foxes had negative results for rVNA before 
shipment to our facility. Foxes were housed for 120 days in an animal biosafety level-2 
facility at the investigator’s facility. Foxes were housed in indoor-outdoor runs (1.1 m in 
aRuby’s Farm, New Sharon, Iowa.
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length × 0.8 m in width) with a climate-controlled block wall pens (4.9 m in length × 0.8 m 
in width) with a heated floor (used in winter) with a chain link door and chain link roof. 
Gray foxes were fed a 1:1 mix of diets formulated for omnivoresb and dogs.c Methods were 
used to enrich the diet and promote consumption. Foxes received peeled hard boiled eggs 
twice weekly, which were alternated with 1/3 can of a beef or a chicken dog food that was 
mixed with the regular diet. Animal use protocols were approved by the Centers for Disease 
Control and Prevention Institutional Animal Care and Use Committee.
RABV vaccine
The RABV PBV vaccine was produced as described elsewhere.18 Briefly, RABV strain 
ERA was attenuated by use of a reverse genetics system.27,28 Amino acid 333 in the 
glycoprotein was altered at the corresponding nucleotide positions in the glycoprotein gene 
by use of site-directed mutagenesis.29–31 The recovered virus, ERAG333, was mixed with 
preservation solution (formulated with or without alginate) and dried via the PBV process. 
Vaccines were suspended in sterile mineral oil and stored with a desiccant for up to 65 days 
at 22° ± 4°C in the dark.
Experimental procedures
Foxes were arbitrarily allocated into 3 groups, and vaccine was endoscopically placed in the 
duodenum of all groups (day 0). Group 1 (2 males and 1 female) received 1 mL of 
nonencapsulated RABV PBV (mean ± SD; 5.2 ± 0.09 log10 ffu/mL), group 2 (3 females) 
received 1 mL of alginate-encapsulated RABV PBV (4.3 ± 0.2 log10 ffu/mL), and group 3 (2 
males) received 1 mL of RABV ERAG333 (from stock stored at −80°C; 8.0 ± 0.2 log10 ffu/
mL).
Food and water was withheld from all foxes for 24 hours prior to endoscopy to allow ingesta 
to pass from the stomach and proximal portions of the intestines, minimize the potential of 
regurgitation during anesthesia, reduce the potential for impeding visual video monitoring, 
and reduce the potential of obstruction of the endoscope and thus placement of the vaccine. 
Food and water were withheld for 24 hours prior to scheduled endoscopy for 1 fox in group 
3; however, endoscopy could not be performed at that time. Because the period for 
withholding of food and water from animals should not exceed 24 hours, this fox received 
food and subsequently had ingesta in its stomach and duodenum at the time of vaccine 
placement (24 hours after the originally scheduled endoscopy).
Each fox was restrained with a catchpole, and anesthesia was induced by administration of a 
combination productd that contained tiletamine HCl–zolazepam HCl (9 mg/kg, IM). Once 
anesthetic induction was confirmed, each fox received atropine (0.04 mg/kg, IM) to reduce 
salivation, and an appropriately sized endotracheal tube with inflatable cuffe was placed and 
secured. Isoflurane (2% to 4%) was administered to establish a surgical plane of anesthesia. 
Foxes were positioned in left lateral recumbency to promote passage of the endoscope into 
bMazuri Omnivore-Zoo Feed ‘A’ 5635, Purina Mills International, St Louis, Mo.
cLab Diet Laboratory Canine Diet 5006, Purina Mills International, St Louis, Mo.
dZoetis, Florham Park, NJ.
eVedco, St Joseph, Mo.
Smith et al. Page 3













the duodenum. A flexible endoscopef was passed through the mouth and into the esophagus. 
Video monitoring confirmed key anatomic landmarks from the oral cavity into the 
esophagus, stomach, pylorus, and opening of the proximal portion of the duodenum. 
Approximately 1 mL of vaccine was placed in the biopsy channel. The vaccine was 
delivered through the channel by the use of air, and the channel then was flushed with sterile 
water. Once placement of the vaccine was confirmed, the endoscope was slowly removed. 
Foxes were monitored constantly until they had recovered from anesthesia. The endoscope 
was washed and disinfected before use in the subsequent fox.
Collection of data and samples
Foxes were purchased and arrived at our facility (day −90). After a 14-day acclimation 
period was completed, a health examination was performed on each fox (day −76). Body 
weight was measured on days −90, −76, 0, 7, 14, 21, and 28. A blood sample (2 mL) was 
collected from each fox immediately before vaccine placement on day 0 and on days, 7, 14, 
21, and 28 after vaccination. Samples were used to determine the rVNA titer by use of a 
rapid fluorescent focus inhibition test.32 Food and water were withheld from the foxes for 24 
hours prior to sedation to avoid regurgitation and possible aspiration. Foxes were restrained 
with a catchpole and sedated by administration of a combination product that contained 
tiletamine HCl–zolazepam HCl (< 9 mg/kg, IM). An area on the ventral aspect of the neck 
or forelimb of the sedated foxes was shaved and scrubbed with alcohol, and blood samples 
were collected from a jugular or cephalic vein by use of a 21-gauge (or smaller gauge) 
needle. Saliva samples were obtained from the sedated foxes at the same time as collection 
of the blood samples. A sterile cotton swab was inserted into the oral cavity, and oral swab 
specimens were used for virus detection with a standard RT-PCR assay for RABV 
nucleocapsid protein gene.33,34 Foxes were monitored constantly until they had recovered 
from sedation.
Necropsy
On day 28, foxes were restrained with a catchpole, anesthetized by administration of 
tiletamine HCl–zolazepam HCl (9 mg/kg, IM), and euthanized by intracardiac 
administration of 2 mL of pentobarbital sodium–phenytoin sodium.g Euthanasia was 
confirmed as a lack of respiratory and cardiac function via stethoscopic auscultation, and 1 
mL of CSF was then collected. Necropsy was performed on each fox, and samples of the 
duodenum, salivary glands, heart, lungs, liver, kidneys, spleen, lumbar spinal cord, and brain 
stem were collected. The RABV antigen was detected by use of direct fluorescent antibody 
testing or immunohistochemical staining, and RABV RNA was detected by use of an RT-
PCR assay.33–35
Statistical analysis
Seroconversion was designated as increase in rVNA titers to > 0.1 U/mL. Two-way Anova 
(alpha = 0.05) with Tukey correction for multiple comparisons (alpha = 0.05, CI = 95%) was 
fOlympus America, Center Valley, Pa.
gMerck & Co, Kenilworth, NJ.
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performed to compare results for mean rVNA over time, among the 3 groups. Values were 
considered significant at P < 0.05.
Results
Animals
All foxes were in good condition and remained healthy throughout the experimental period. 
Overall, the mean body weight of all the groups increased; however, males gained more 
weight than did females (Figure 1). All foxes recovered well from endoscopic placement of 
the vaccine, and the procedures did not result in inappetence. Foxes were observed daily, and 
no clinical signs of rabies were observed in any animal.
Vaccination response
Values for rVNA did not differ significantly among the groups. Two of 3 foxes of group 1 
(received nonencapsulated RABV PBV) seroconverted (titer > 0.1 U/mL) by day 14, and 
titers continued to increase until the end of the study. The titer of both animals on day 28 
was 1.2 U/ml. One of 2 foxes of group 3 (received RABV ERAG333) seroconverted by day 
14, and the titer of that animal continued to increase until the end of the study (titer on day 
28 was 1.6 U/ml). Administration of both nonencapsulated RABV PBV and ERAG333 
induced similar titers on day 28. The other fox of group 3 may have failed to seroconvert 
because of bile inactivation of the live RABV because this fox had food in its stomach at the 
time of endoscopy (see Experimental procedures in Material and Methods). None of the 
foxes of group 2 (alginate-encapsulated RABV PBV) seroconverted. Some weak virus 
neutralization was observed in 1 fox of group 2. The titer on days, 7, 14, 21 and 28 was 0.07, 
0.06, < 0.05, and 0.1 U/ml, respectively.
Examination of oral swab specimens obtained during the study was performed. No RABV 
RNA was detected on any day of the study.
Necropsy
None of the foxes had evidence of rVNA in the CSF on day 28. None of the foxes had 
evidence of RABV infection in the lumbar spinal cord or brain stem on day 28, as 
determined by use of direct fluorescent antibody staining. Finally, RABV RNA was not 
detected in any tissues obtained from any of the foxes on day 28.
Discussion
Results for the study reported here indicated that the response to vaccination was attributable 
to delivery of live RABV vaccine to the duodenal mucosa of gray foxes. On the basis of 
results for the 3 foxes that seroconverted, geometric mean ± SD titer increased from 0.28 
± 0.03 U/mL on day 14 to 1.3 ± 0.2 U/mL on day 28. The rVNA did not differ significantly 
among the groups. However, the results were clinically relevant because RABV PBV 
vaccine placed endoscopically in the duodenum induced rabies virus neutralizing antibody 
titers greater than the World Organization for Animal Health recommended value of 0.5 
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U/mL.36 On the basis of the present proof-of-concept study, thermostable RABV PBV may 
have use as part of oral vaccination programs in the future.
The RABV PBV vaccines were suspended in sterile mineral oil, whereas, the control RABV 
was delivered in an aqueous solution. Mineral oil may have protected the nonencapsulated 
RABV PBV from bile or acted as an adjuvant to allow the virus to persist at the target site 
and increase the chances of activating an immune response. Future formulations should 
include bile inhibitors, mineral oil, or both.
The alginate-encapsulated vaccine failed to stimulate an immune response. This formulation 
of the vaccine resulted in a lower mean ± SD RABV titer, compared with the mean titer for 
the nonencapsulated vaccine and control RABV, which may not have been sufficient to 
stimulate an immune response. By comparison, other studies18,30,37 with live-attenuated 
RABV vaccines involved formulations at 4.4 log10 ffu/mL to 9.3 log10 ffu/mL. Because the 
vaccine was a live-attenuated virus, viral replication should have negated any differences in 
the initial titer. Previous attempts23,28 to target the intestinal mucosa by use of alginate-
encapsulated vaccines have been successful. Delivery of the alginate-encapsulated vaccine 
through the biopsy channel may have been hindered because the encapsulated vaccine was 
more viscous than the nonencapsulated vaccine. Concerns about dose and the problem of 
inactivation by bile could be resolved by use of a capsulated vaccine that is designed to 
target the intestinal mucosa and is delivered orally to animals in their regular diet.
Although the present study was not designed to detect viral shedding, which may occur 
within the first 48 hours after oral vaccination,39,40 we did not detect viral shedding in saliva 
samples obtained at the times of blood collection. Any localized viral replication was cleared 
by day 28 such that no evidence of infection could be detected in the tissue samples 
collected during necropsy. None of the foxes developed rabies, and all nerve tissue and CSF 
obtained on day 28 had negative results when tested for RABV. Future studies to examine 
possible viral shedding in feces and to evaluate oral delivery methods could be completed in 
red foxes because this is an established and more accessible animal used for rabies research. 
Overall, the results of the study reported here added to the evidence that RABV PBV may be 
formulated into a vaccine for domestic or wild animals and supported future testing of the 
desired method of delivery in target species.
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Mean ± SD percentage change in body weight of gray foxes (Urocyon cinereoargenteus) 
administered RABV vaccine on the basis of group (A) and on the basis of sex (B). Body 
weight was obtained at the time of arrival at our facility (day −90), at a health examination 
performed after a 14-day acclimation period (day −76), before endoscopic delivery of 
vaccine (day 0), and at the time of blood collection on days 7, 14, 21, and 28. Mean and SD 
were calculated for each group by the percentage change for each fox calculated by use of 
the body weight obtained on day −76 as the denominator. In panel A, results are reported for 
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all 8 foxes (black circles), 3 foxes (2 males and 1 female) that received 1 mL of 
nonencapsulated RABV PBV (mean ± SD; 5.2 ± 0.09 log10 ffu/mL; group 1 [black 
squares]), 3 foxes (3 females) that received 1 mL of alginate-encapsulated RABV PBV (4.3 
± 0.2 log10 ffu/mL; group 2 [black triangles]), and 2 foxes (2 males) that received 1 mL of 
RABV ERAG333 (8.0 ± 0.2 log10 ffu/mL; group 3 [inverted black triangles]). In panel B, 
results are reported for all 8 foxes (black circles), the 4 female foxes (white circles), and the 
4 male foxes (white squares).
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